European Commission Approves OPUVIZ™ (SB15), a Biosimilar to Eylea, for Treatment of Retinal Disorders

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution...

November 19, 2024 | Tuesday | News
Tirzepatide Significantly Reduces Heart Failure Risk in Obese Patients with Preserved Ejection Fraction, New Data Show

Eli Lilly and Company (NYSE: LLY) announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening ...

November 18, 2024 | Monday | News
EMA Committee Recommends Approval of Opdivo® + Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

November 18, 2024 | Monday | News
EMA CHMP Issues Positive Opinion for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

November 15, 2024 | Friday | News
GSK’s Blenrep Combination Demonstrates Significant Survival Benefit in Relapsed/Refractory Multiple Myeloma

GSK plc (LSE/NYSE: GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Bl...

November 15, 2024 | Friday | News
EMA Committee Recommends Approval of Sarclisa in Combination with VRd for Transplant-Ineligible Multiple Myeloma

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval ...

November 15, 2024 | Friday | News
MSD Acquires Global License for LM-299, a Novel PD-1/VEGF Bispecific Antibody from LaNova Medicines

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology ...

November 15, 2024 | Friday | News
BioNTech Acquires Biotheus to Strengthen Oncology Pipeline with Bispecific Antibody Asset BNT327/PM8002

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for...

November 14, 2024 | Thursday | News
Gilead’s Lenacapavir Demonstrates Strong Efficacy and High Adherence in Phase 3 PURPOSE 2 Trial for HIV Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stu...

November 14, 2024 | Thursday | News
TAE Life Sciences and Stella Pharma Announce Exclusive Collaboration to Expand BNCT Therapy in the U.S. and Europe

TAE Life Sciences (TLS), a leader in boron neutron capture therapy (BNCT) technology, and Stella Pharma, the pioneering developer of the boronophenylalan...

November 14, 2024 | Thursday | News
NurExone Gains EMA Orphan Designation for ExoPTEN, Advancing Spinal Cord Injury Therapy Across Europe

NurExone Biologic Inc.  a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medici...

November 14, 2024 | Thursday | News
GenScript Biotech Global Forum 2024: Paving the Way for Innovation and Investment in Cell and Gene Therapy

- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...

November 14, 2024 | Thursday | News
TrakCel's OCELLOS Platform Chosen to Support Five Key Cell Therapy Products in 2024, Streamlining CGT Supply Chain Management

TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions for the precise management, control and tracking of CGTs has announce...

November 13, 2024 | Wednesday | News
Adragos Pharma Expands Production with €13 Million Investment in New Ampoule Filling Line, Boosting Capacity by 30%

Adragos Pharma, a leading Contract Development & Manufacturing Organisation (CDMO), has significantly enhanced its production capabilities with the com...

November 13, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close